On October 7, 2020 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, reported that it has been informed by the European Patent Office that the examining division intends to grant the company a European Patent for the Company’s application titled "A System and Method for High Throughput Screening of Cancer Cells (Press release, Cannabics Pharmaceuticals, OCT 27, 2020, View Source [SID1234570699])."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Drug Sensitivity Heatmap of Multiple Cannabinoids and Cancer Cells
This patent application relates to the company’s CANNABICS CDx companion diagnostic drug sensitivity test, whereby a patient’s biopsy is screened to match the optimal cannabinoid combination available using the company’s high throughput screening of cancer cells proprietary technology.
Outside the European territory, this patent is also currently being reviewed in other territories including the US and Canada. The decision of the European examiner is significant in that it could also accelerate the review process in other territories who offer a Patent Prosecution Highway such as Canada, India, Mexico and Brazil.
Gabriel Yariv, Cannabics Pharmaceuticals’ President and COO said: "This patent exemplifies our pioneering vision to bring Cannabinoid-based therapies and treatments to cancer patients worldwide and will strengthen our position as we concentrate on penetrating the European market".
Dr. Eyal Ballan, Cannabics Pharmaceuticals’ CTO, said:" As pioneers in Cannabinoid-based Cancer diagnostics, we have always believed in the novelty and uniqueness of our vision to personalize cannabinoid treatments. The intention of the European examiner to grant our patent is certainly a positive vindication for our efforts".